玻璃体切除术联合玻璃体内地塞米松植入物对增殖性糖尿病视网膜病变患者视力结局的有效性:一项前瞻性随机对照试验的研究方案
本研究为单盲随机对照试验,计划纳入100例需行玻璃体切除术的增殖性糖尿病视网膜病变(PDR)患者,随机分为Ozurdex(0.7 mg地塞米松玻璃体内植入物)联合玻璃体切除术组与单纯玻璃体切除术组,评估联合治疗对视力结局及黄斑形态的影响,主要和次要结局在基线及术后4、8、12、24周评估。
要点
- 纳入100例需行玻璃体切除术的PDR患者,随机分为联合地塞米松植入物组与单纯手术组。
- 地塞米松植入物组接受玻璃体切除术联合0.7 mg地塞米松玻璃体内植入物,对照组仅行玻璃体切除术。
- 主要和次要结局在基线及术后4、8、12、24周评估。
核心结论
- 本方案旨在增进对Ozurdex 0.7 mg地塞米松植入物联合玻璃体切除术治疗PDR晚期并发症时对视力和黄斑形态变化影响的理解。
研究设计与样本
- 单盲随机对照试验,计划纳入100例诊断为PDR且需行玻璃体切除术的参与者。
- 参与者随机分配至Ozurdex(0.7 mg地塞米松玻璃体内植入物)组或对照组。
- 地塞米松植入物组行玻璃体切除术联合0.7 mg地塞米松玻璃体内植入物,对照组仅行玻璃体切除术。
- 所有玻璃体切除术由单一外科医生完成,玻璃体内地塞米松植入物的选择在巩膜伤口关闭前披露。
- 主要和次要结局在基线及玻璃体切除术后4、8、12、24周评估。
关键数值与推荐
- 使用R软件进行统计分析,p值0.05视为具有统计学显著性。
- 视力和OCT测量采用重复测量方差分析(ANOVA)及双尾检验分析。
- 视力改善率、视力下降率、术后玻璃体出血、眼压升高和术后视网膜脱离的发生率采用卡方检验及双尾检验分析。
- 采用逻辑回归分析视力预后不良、新生血管性青光眼发生和术后玻璃体出血发生的危险因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proliferative diabetic retinopathy (PDR) often leads to tractional retinal detachment and vitreous hemorrhage, requiring vitrectomy. Poor visual outcomes are commonly caused by macular edema and proliferative vitreous retinopathy after vitrectomy. Intravitreal dexamethasone implant has shown promise in improving visual function after vitrectomy for diabetic macular edema, but its role in vitrectomy for PDR treatment remains unexplored. This study aims to assess the effectiveness of vitrectomy combined with an intravitreal dexamethasone implant for PDR patients. METHODS: We will design a single-mask, randomized controlled trial with 100 participants diagnosed with PDR requiring vitrectomy. Participants will be randomly assigned to either the Ozurdex (0.7 mg dexamethasone intravitreal implant) group or the control group. The dexamethasone implant group will undergo vitrectomy combined with 0.7 mg dexamethasone intravitreal implant, while the control group will undergo vitrectomy alone. A single surgeon will perform all the vitrectomy surgeries, and the choice of intravitreal dexamethasone implant treatment will be disclosed before the closure of scleral wounds. Primary and secondary outcomes will be assessed at baseline and at 4, 8, 12, and 24 weeks post-vitrectomy. STATISTICAL ANALYSIS: Statistical analysis will be conducted using R software. A p value 0.05 will be considered statistically significant. The analysis methods will include the following: visual acuity and OCT measurements will be analyzed using repeated measures analysis of variance (ANOVA) with two-tailed tests; rates of visual improvement, visual decline, postoperative vitreous hemorrhage, elevated intraocular pressure, and postoperative retinal detachment will be analyzed using chi-square tests with two-tailed tests. Logistic regression analysis will be used to analyze risk factors for poor visual prognosis, neovascular glaucoma development, and postoperative vitreous hemorrhage occurrence. DISCUSSION: This protocol aims to enhance our understanding of the effects of combining an intravitreal Ozurdex 0.7 mg dexamethasone implant with vitrectomy on visual outcomes and macular morphology changes in treating late complications of PDR. TRIAL REGISTRATION: The trial was registered at the Chinese Clinical Trial Registry on May 11, 2022, with registration number ChiCTR2200059760.
引用
- Li J, Wang Z, Chandra A, et al. The effectiveness of vitrectomy co-adjuvant intravitreal dexamethasone implant on visual outcome in patients with proliferative diabetic retinopathy: study protocol for a prospective randomized controlled trial. Trials. 2025. PMID: 39939840. doi:10.1186/s13063-025-08758-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。